Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Subscribe To Our Newsletter & Stay Updated
